Prof Amy Burd speaks to ecancer at the 2019 ASH meeting in Orlando about results from the Beat AML master trial.

She reports that they achieved the primary endpoint of the study, with 94.7% of patients able to make a treatment decision within seven days.

Dr Burd also reports that there was a superior overall survival for patients treated within the Beat AML study compared to patients that were treated with standard of care.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

свернуть